Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib + Cyclophosphamide in Refractory Ovarian, TNBC, and NHL
NCT01306032Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of veliparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), triple-negative breast cancer (TNBC), non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Started Jan 2011; status: completed.
02
Drugs
veliparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)triple-negative breast cancer (TNBC)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01306032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306032.